Bailard’s Sage Therapeutics SAGE Stock Holding History

Bailard’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,500	Closed	-$275K	–	674
2020 Q3	$275K	Buy	+4,500	New	+$228K	0.01%	403
2019 Q4	–	Sell	-1,700	Closed	-$238K	–	602
2019 Q3	$238K	Hold	1,700	–	–	0.01%	443
2019 Q2	$311K	Hold	1,700	–	–	0.02%	404
2019 Q1	$270K	Buy	+1,700	New	+$246K	0.02%	440
2018 Q4	–	Sell	-1,700	Closed	-$240K	–	546
2018 Q3	$240K	Hold	1,700	–	–	0.01%	494
2018 Q2	$266K	Hold	1,700	–	–	0.02%	462
2018 Q1	$274K	Hold	1,700	–	–	0.02%	426
2017 Q4	$280K	Buy	+1,700	New	+$165K	0.02%	382

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bailard's SAGE Position: Q4 2020 in Review

Bailard sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 4,500 shares — an estimated $275K sold.

Bailard first reported a position in SAGE in Q4 2017 and held it in 8 quarters. The position peaked at $311K in Q2 2019. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

Bailard reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
Bailard sold 4,500 Sage Therapeutics shares in Q4 2020, an estimated $275K.
Bailard first reported a position in Sage Therapeutics in Q4 2017 and held it in 8 quarters.
Bailard's Sage Therapeutics position peaked at $311K in Q2 2019.
249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Bailard's 13F filing for Q4 2020, filed 3 Feb 2021.